Treatment of children under 4 years of age with medulloblastoma and ependymoma in the HIT2000/HIT-REZ 2005 trials: Neuropsychological outcome 5 years after treatment

Young children with brain tumours are at high risk of developing treatment-related sequelae. We aimed to assess neuropsychological outcomes 5 years after treatment. This cross-sectional study included children under 4 years of age with medulloblastoma (MB) or ependymoma (EP) enrolled in the German b...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 15; no. 1; p. e0227693
Main Authors Ottensmeier, Holger, Schlegel, Paul G, Eyrich, Matthias, Wolff, Johannes E, Juhnke, Björn-Ole, von Hoff, Katja, Frahsek, Stefanie, Schmidt, Rene, Faldum, Andreas, Fleischhack, Gudrun, von Bueren, Andre, Friedrich, Carsten, Resch, Anika, Warmuth-Metz, Monika, Krauss, Jürgen, Kortmann, Rolf D, Bode, Udo, Kühl, Joachim, Rutkowski, Stefan
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 23.01.2020
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Young children with brain tumours are at high risk of developing treatment-related sequelae. We aimed to assess neuropsychological outcomes 5 years after treatment. This cross-sectional study included children under 4 years of age with medulloblastoma (MB) or ependymoma (EP) enrolled in the German brain tumour trials HIT2000 and HIT-REZ2005. Testing was performed using the validated Wuerzburg Intelligence Diagnostics (WUEP-D), which includes Kaufman-Assessment-Battery, Coloured Progressive Matrices, Visual-Motor Integration, finger tapping "Speed", and the Continuous Performance Test. Of 104 patients in 47 centres, 72 were eligible for analyses. We assessed whether IQ was impacted by disease extent, disease location, patient age, gender, age at surgery, and treatment (chemotherapy with our without craniospinal irradiation [CSI] or local radiotherapy [LRT]). Median age at surgery was 2.3 years. Testing was performed at a median of 4.9 years after surgery. Patients with infratentorial EPs (treated with LRT) scored highest in fluid intelligence (CPM 100.9±16.9, mean±SD); second best scores were achieved by patients with MB without metastasis treated with chemotherapy alone (CPM 93.9±13.2), followed by patients with supratentorial EPs treated with LRT. In contrast, lowest scores were achieved by patients that received chemotherapy and CSI, which included children with metastasised MB and those with relapsed MB M0 (CPM 71.7±8.0 and 73.2±21.8, respectively). Fine motor skills were reduced in all groups. Multivariable analysis revealed that type of treatment had an impact on IQ, but essentially not age at surgery, time since surgery or gender. Our results confirm previous reports on the detrimental effects of CSI in a larger cohort of children. Comparable IQ scores in children with MB treated only with chemotherapy and in children with EP suggest that this treatment strategy represents an attractive option for children who have a high chance to avoid application of CSI. Longitudinal follow-up examinations are warranted to assess long-term neuropsychological outcomes.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Competing Interests: J.E.W. is currently a employee of AbbVie, but during the trial and data analysis he served as a clinical neurooncologist in several hospitals, lastly Cleveland Clinic, Ohio. His employment has no impact on the results of this trial. Furthermore, this does not alter our adherence to PLOS ONE policies on sharing data and materials. No other author has any competing interest to declare.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0227693